PUBLICATION

Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis

Authors
He, Y., Gong, G., Quijas, G., Lee, S.M., Chaudhuri, R.K., Bojanowski, K.
ID
ZDB-PUB-250119-6
Date
2025
Source
FEBS Open Bio : (Journal)
Registered Authors
Keywords
IDMF, Jurkat, fumarate, microglia, multiple sclerosis, psoriasis, zebrafish
MeSH Terms
  • Dimethyl Fumarate*/analogs & derivatives
  • Dimethyl Fumarate*/pharmacology
  • Dimethyl Fumarate*/therapeutic use
  • Multiple Sclerosis*/drug therapy
  • Animals
  • Skin/drug effects
  • Disease Models, Animal
  • Zebrafish
  • Jurkat Cells
  • Humans
  • Psoriasis*/drug therapy
  • Mice
  • Microglia/drug effects
PubMed
39825608 Full text @ FEBS Open Bio
Abstract
Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis. Isosorbide di-(methyl fumarate) (IDMF), a novel derivative of DMF, was synthesized to circumvent this adverse reaction and unlock the potential of topical delivery, which could be useful for treating psoriasis in the subpopulation of psoriatic MS patients, as well as in the general population. Here, we compared its therapeutic potential of this non-sensitizing derivative with DMF and its therapeutic version Diroximel in three skin- and neuroinflammation models: the lck-GFP zebrafish, activated BV-2 murine microglia and human T-lymphocyte Jurkat cell line. The results provide a comparative evaluation of the bioactivity of these three related chemical entities in models relevant to skin and neuroinflammation and expose several therapeutic advantages unique to IDMF.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping